PTPRC and acute myeloid leukemia: Treatment with lipid nanoparticle (LNP)-formulated anti-HOXB-AS3 gapmers led to downregulation of HOXB-AS3 expression in human CD45-selected AML blasts isolated from the BM of the treated mice (P < 0.001; Fig. 3c).